Edition:
United Kingdom

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

88.22USD
13 Nov 2018
Change (% chg)

$-1.47 (-1.64%)
Prev Close
$89.69
Open
$90.00
Day's High
$90.81
Day's Low
$88.20
Volume
2,837,773
Avg. Vol
1,499,362
52-wk High
$125.84
52-wk Low
$77.50

Latest Key Developments (Source: Significant Developments)

Medicines Patent Pool Signs Licence With AbbVie To Expand Access To Hep-C Treatment glecaprevir/pibrentasvir
Monday, 12 Nov 2018 

Nov 12 (Reuters) - The Medicines Patent Pool:THE MEDICINES PATENT POOL SIGNS LICENCE WITH ABBVIE TO EXPAND ACCESS TO KEY HEPATITIS C TREATMENT, GLECAPREVIR/PIBRENTASVIR.MEDICINES PATENT POOL SAYS COLLABORATION WITH ABBVIE WILL ENSURE AFFORDABLE HEPATITIS C TREATMENT OPTIONS IN LOW- AND MIDDLE-INCOME COUNTRIES .  Full Article

Abbvie Receives European Commission Approval Of Venclyxto Plus Rituximab For Treatment Of Patients With Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - AbbVie Inc ::ABBVIE RECEIVES EUROPEAN COMMISSION APPROVAL OF VENCLYXTO® (VENETOCLAX) PLUS RITUXIMAB FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY.APPROVAL IS BASED ON MURANO PHASE 3 CLINICAL TRIAL.  Full Article

Galapagos 9-Month Revenue Rises To 205.1 Million Euros
Wednesday, 24 Oct 2018 

Oct 25 (Reuters) - GALAPAGOS ::REPORTED ON WEDNESDAY 9-MONTH GROUP REVENUES INCREASED BY EUR 98.7 MILLION TO EUR 205.1 MILLION.9-MONTH OPERATING LOSS DECREASED BY EUR 9.1 MILLION TO EUR 53.5 MILLION.9-MONTH NET LOSS DECREASED BY EUR 41.7 MILLION TO EUR 44.2 MILLION.CASH AND CASH EQUIVALENTS ON 30 SEPT 2018 OF EUR1,343.7 MILLION.IN Q4, EXPECTS TO PRESENT MORE DETAILED FINDINGS FROM THE EQUATOR, TORTUGA, AND FINCH 2 TRIALS WITH FILGOTINIB.WILL ALSO PRESENT FIRST DATA AND DEVELOPMENT STRATEGY WITH REGARD TO TOLEDO, OUR NEW PROGRAM IN INFLAMMATORY INDICATIONS.EXPECT TO START DOSING IN THE ISABELA (PH3 IPF `1690) AND PINTA (PH2 IPF `1205) PATIENT TRIALS.DUE TO REVISION OF THE ABBVIE COLLABORATION AGREEMENT IN CF, CO IS REDUCING EXPECTED OPERATIONAL CASH BURN FROM THE LAST GUIDED EUR180-200 MILLION TO EUR140-160 MILLION IN 2018.  Full Article

Positive Phase 2B Data For AbbVie's Upadacitinib Show Significant Induction Of Clinical Remission, Response In Patients
Monday, 22 Oct 2018 

Oct 22 (Reuters) - AbbVie Inc ::POSITIVE PHASE 2B DATA FOR ABBVIE'S UPADACITINIB SHOW SIGNIFICANT INDUCTION OF CLINICAL REMISSION AND RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS.IN U-ACHIEVE, UPADACITINIB (15/30/45 MG, ONCE DAILY) MET PRIMARY ENDPOINT OF CLINICAL REMISSION & ALL RANKED SECONDARY ENDPOINTS.UPADACITINIB 7.5 MG GROUP DID NOT MEET PRIMARY ENDPOINT.SERIOUS ADVERSE EVENTS OCCURRED IN 0/4/6/5 PERCENT OF 7.5/15/30/45 MG UPADACITINIB GROUPS, RESPECTIVELY.NO NEW SAFETY SIGNALS WERE DETECTED IN STUDY.NO VENOUS THROMBOEMBOLIC EVENTS, MAJOR ADVERSE CARDIOVASCULAR EVENTS OR DEATHS OCCURRED.OVERALL SAFETY PROFILE WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED PHASE 2 CROHN'S DISEASE STUDY.PHASE 3 TRIALS FOR UPADACITINIB IN ULCERATIVE COLITIS HAVE BEEN INITIATED.  Full Article

AbbVie Says Robert Michael Appointed CFO
Friday, 19 Oct 2018 

Oct 19 (Reuters) - AbbVie Inc ::SAYS ROBERT A. MICHAEL APPOINTED CFO.WILLIAM J. CHASE, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER, INFORMED ABBVIE THAT HE PLANS TO RETIRE FROM COMPANY IN MID-2019.ABBVIE SAYS WILLIAM J. CHASE, EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER, INFORMED ABBVIE THAT HE PLANS TO RETIRE FROM THE COMPANY IN MID-2019.  Full Article

Abbvie Announces Resolution Of Humira Patent Disputes With Fresenius Kabi
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES GLOBAL RESOLUTION OF HUMIRA (ADALIMUMAB) PATENT DISPUTES WITH FRESENIUS KABI.ABBVIE INC - AGREEMENTS PROVIDE NON-EXCLUSIVE LICENSE TO FRESENIUS KABI FOR HUMIRA-RELATED INTELLECTUAL PROPERTY IN U.S. EFFECTIVE SEPTEMBER 30, 2023.ABBVIE INC - FRESENIUS KABI ACKNOWLEDGES VALIDITY OF ABBVIE'S INTELLECTUAL PROPERTY FOR HUMIRA.ABBVIE INC - PRECISE TERMS ARE CONFIDENTIAL BETWEEN PARTIES.ABBVIE INC - ALL LITIGATION PENDING BETWEEN PARTIES WILL BE DISMISSED.  Full Article

Abbvie, Morphic Therapeutic Announce Collaboration Targeting Fibrotic Diseases
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - AbbVie Inc ::ABBVIE SAYS WILL PAY MORPHIC UPFRONT PAYMENT OF $100 MILLION FOR EXCLUSIVE LICENSE OPTIONS ON PRODUCT CANDIDATES.ABBVIE AND MORPHIC THERAPEUTIC ANNOUNCE COLLABORATION TARGETING FIBROTIC DISEASES.ABBVIE SAYS MORPHIC RETAINS COST-SHARING RIGHTS IN DEVELOPMENT OF LIVER FIBROSIS INDICATIONS.ABBVIE SAYS MORPHIC MAY OPT INTO PAYING A PERCENT OF CO'S DEVELOPMENT COSTS IN EXCHANGE FOR ENHANCED ROYALTIES.  Full Article

Abbvie Sets Qtrly Cash Dividend Of $0.96/Share
Friday, 7 Sep 2018 

Sept 8 (Reuters) - AbbVie Inc ::SETS QUARTERLY CASH DIVIDEND OF $0.96PER SHARE.  Full Article

Abbvie Enters Into Credit Agreement For $3.0 Bln
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - AbbVie Inc ::ABBVIE SAYS ON AUG 31, ENTERED INTO REVOLVING CREDIT AGREEMENT - SEC FILING.ABBVIE INC - CREDIT AGREEMENT PROVIDES FOR $3.0 BILLION UNSECURED REVOLVING CREDIT FACILITY.ABBVIE INC - TERMINATED ALL COMMITMENTS OUTSTANDING UNDER REVOLVING CREDIT AGREEMENT, DATED AUGUST 18, 2014.  Full Article

Abbvie Announces Imbruvica Plus Rituximab Approval By U.S. FDA For A Rare Type Of Blood Cancer
Monday, 27 Aug 2018 

Aug 27 (Reuters) - AbbVie Inc ::ABBVIE ANNOUNCES IMBRUVICA® (IBRUTINIB) PLUS RITUXIMAB APPROVAL BY U.S. FDA AS FIRST CHEMOTHERAPY-FREE COMBINATION TREATMENT IN ADULTS WITH WALDENSTRÖM'S MACROGLOBULINEMIA, A RARE TYPE OF BLOOD CANCER.ABBVIE INC - IMBRUVICA NOW HAS A TOTAL OF NINE FDA APPROVALS ACROSS SIX DIFFERENT DISEASES.ABBVIE INC - FDA APPROVED IMBRUVICA (IBRUTINIB) PLUS RITUXIMAB FOR TREATMENT OF ADULT PATIENTS WITH A TYPE OF NON-HODGKIN'S LYMPHOMA.  Full Article

Photo

Walmart, Home Depot adopt health insurer tactic in drug copay battle

NEW YORK Walmart and Home Depot , two of the top 10 U.S. employers, have embraced a health insurance strategy that punishes drugmakers for using discount cards to keep patients from switching or stopping their medications.